7AE107A7-8EA7-4920-A579-2337C007920D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 31.340341655716163
- age_years
- 42
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.535
- MYC_TARGETS_V1+0.497
- OXIDATIVE_PHOSPHORYLATION+0.397
- DNA_REPAIR+0.389
- UNFOLDED_PROTEIN_RESPONSE+0.365
- TGF_BETA_SIGNALING+0.279
- ADIPOGENESIS+0.272
- G2M_CHECKPOINT+0.269
- E2F_TARGETS+0.266
- MITOTIC_SPINDLE+0.197
Top 10 suppressed
- KRAS_SIGNALING_DN-0.411
- MYOGENESIS-0.322
- PANCREAS_BETA_CELLS-0.318
- INFLAMMATORY_RESPONSE-0.301
- ANGIOGENESIS-0.293
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.275
- COAGULATION-0.254
- SPERMATOGENESIS-0.207
- ESTROGEN_RESPONSE_LATE-0.205
- KRAS_SIGNALING_UP-0.189
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.899 |
| 2 | F56466DC-3C0F-48BE-8A72-CEDEAEF52F00 | — | — | 0.891 |
| 3 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.887 |
| 4 | 6EE50ED0-9F0E-4393-B165-257D5C03F221 | — | — | 0.885 |
| 5 | A6FB1BEE-0D36-480C-8619-1FA82583FCD1 | — | — | 0.880 |
| 6 | 8BC036E8-0EA0-4346-A551-2A5F8975FEAB | — | — | 0.878 |
| 7 | 72781523-C5BA-4B54-8410-E238B5F441B4 | — | — | 0.877 |
| 8 | 94F9B9B1-A23E-4947-BD09-67CBA3052C51 | — | — | 0.876 |
| 9 | E81FA8B7-3FFE-4F73-94AF-0B5257D7F81A | — | — | 0.871 |
| 10 | DEB3BE77-120D-4EC5-AA7A-4B2952F2C832 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.535 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.497 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.397 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.389 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.365 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.279 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.272 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.269 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.266 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.197 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.191 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.181 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.157 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.153 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.126 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.103 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.103 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.092 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.076 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.074 | Inavolisib | — uncovered |